JAMA reports manufacturer-sponsored coupon use fell from 2017 to 2024, but per-claim coupon amounts increased, particularly for obesity and diabetes therapies, implying shifting pricing and patient cost-offset strategies.
Manufacturer-sponsored coupon use for brand-name drugs declined from 2017 to 2024 among US patients
but per-claim coupon amounts increased
especially for #Obesity and #Diabetes therapies.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare